GB0304634D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB0304634D0
GB0304634D0 GBGB0304634.9A GB0304634A GB0304634D0 GB 0304634 D0 GB0304634 D0 GB 0304634D0 GB 0304634 A GB0304634 A GB 0304634A GB 0304634 D0 GB0304634 D0 GB 0304634D0
Authority
GB
United Kingdom
Prior art keywords
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0304634.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0304634.9A priority Critical patent/GB0304634D0/en
Publication of GB0304634D0 publication Critical patent/GB0304634D0/en
Priority to EP04714791A priority patent/EP1597368A2/en
Priority to KR1020057016076A priority patent/KR20050107472A/ko
Priority to JP2006501975A priority patent/JP2007524352A/ja
Priority to RU2005125608/13A priority patent/RU2005125608A/ru
Priority to US10/547,207 priority patent/US20060147458A1/en
Priority to BRPI0407601-0A priority patent/BRPI0407601A/pt
Priority to PCT/EP2004/002007 priority patent/WO2004076665A2/en
Priority to MXPA05009160A priority patent/MXPA05009160A/es
Priority to CA002517062A priority patent/CA2517062A1/en
Priority to CNA2004800052301A priority patent/CN1753994A/zh
Priority to AU2004215187A priority patent/AU2004215187A1/en
Priority to PL378761A priority patent/PL378761A1/pl
Priority to IS7956A priority patent/IS7956A/is
Priority to ZA200506548A priority patent/ZA200506548B/en
Priority to CO05084394A priority patent/CO5670372A2/es
Priority to NO20054102A priority patent/NO20054102L/no
Priority to MA28489A priority patent/MA27746A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0304634.9A 2003-02-28 2003-02-28 Vaccines Ceased GB0304634D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0304634.9A GB0304634D0 (en) 2003-02-28 2003-02-28 Vaccines
PL378761A PL378761A1 (pl) 2003-02-28 2004-02-26 Szczepionki
MXPA05009160A MXPA05009160A (es) 2003-02-28 2004-02-26 Vacunas derivadas de mucina de celula epitelial muc-1.
CNA2004800052301A CN1753994A (zh) 2003-02-28 2004-02-26 疫苗
JP2006501975A JP2007524352A (ja) 2003-02-28 2004-02-26 上皮細胞ムチンｍｕｃ−１から誘導されるワクチン
RU2005125608/13A RU2005125608A (ru) 2003-02-28 2004-02-26 Вакцины на основе муцина muc-1 эпителиальных клеток
US10/547,207 US20060147458A1 (en) 2003-02-28 2004-02-26 Vaccines
BRPI0407601-0A BRPI0407601A (pt) 2003-02-28 2004-02-26 molécula de ácido nucleico, plasmìdeo, composição farmacêutica, uso de nmolécula de ácido nucleico, e método de tratamento ou de prevenção de tumores
PCT/EP2004/002007 WO2004076665A2 (en) 2003-02-28 2004-02-26 Vaccines derived from epithelial cell mucin muc-1
EP04714791A EP1597368A2 (en) 2003-02-28 2004-02-26 Vaccines derived from epithelial cell mucin muc-1
CA002517062A CA2517062A1 (en) 2003-02-28 2004-02-26 Vaccines derived from epithelial cell mucin muc-1
KR1020057016076A KR20050107472A (ko) 2003-02-28 2004-02-26 상피세포 뮤신 muc-1으로부터 유래된 백신
AU2004215187A AU2004215187A1 (en) 2003-02-28 2004-02-26 Vaccines derived from epithelial cell mucin MUC-1
IS7956A IS7956A (is) 2003-02-28 2005-07-25 Bóluefni afleidd úr þekjufrumu músín MUC-1
ZA200506548A ZA200506548B (en) 2003-02-28 2005-08-16 Vaccines derived from epithelial cell mucin MUC-1
CO05084394A CO5670372A2 (es) 2003-02-28 2005-08-24 Vacuna derivadas de mucina de celula epitelial muc-1
NO20054102A NO20054102L (no) 2003-02-28 2005-09-02 Vaksiner avledet fra epitelial celle mucin Muc-1
MA28489A MA27746A1 (fr) 2003-02-28 2005-09-09 Vaccins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0304634.9A GB0304634D0 (en) 2003-02-28 2003-02-28 Vaccines

Publications (1)

Publication Number Publication Date
GB0304634D0 true GB0304634D0 (en) 2003-04-02

Family

ID=9953871

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0304634.9A Ceased GB0304634D0 (en) 2003-02-28 2003-02-28 Vaccines

Country Status (18)

Country Link
US (1) US20060147458A1 (es)
EP (1) EP1597368A2 (es)
JP (1) JP2007524352A (es)
KR (1) KR20050107472A (es)
CN (1) CN1753994A (es)
AU (1) AU2004215187A1 (es)
BR (1) BRPI0407601A (es)
CA (1) CA2517062A1 (es)
CO (1) CO5670372A2 (es)
GB (1) GB0304634D0 (es)
IS (1) IS7956A (es)
MA (1) MA27746A1 (es)
MX (1) MXPA05009160A (es)
NO (1) NO20054102L (es)
PL (1) PL378761A1 (es)
RU (1) RU2005125608A (es)
WO (1) WO2004076665A2 (es)
ZA (1) ZA200506548B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
CN103570821A (zh) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
CA3036799A1 (en) 2016-09-28 2018-04-05 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
CN114230655A (zh) * 2021-03-24 2022-03-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用
WO2023122526A1 (en) * 2021-12-20 2023-06-29 Zoetis Services Llc Use of interferon as an adjuvant in vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE60030450T2 (de) * 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
MA27746A1 (fr) 2006-02-01
CN1753994A (zh) 2006-03-29
AU2004215187A1 (en) 2004-09-10
CO5670372A2 (es) 2006-08-31
ZA200506548B (en) 2007-12-27
EP1597368A2 (en) 2005-11-23
BRPI0407601A (pt) 2006-02-14
KR20050107472A (ko) 2005-11-11
CA2517062A1 (en) 2004-09-10
NO20054102D0 (no) 2005-09-02
WO2004076665A2 (en) 2004-09-10
PL378761A1 (pl) 2006-05-15
RU2005125608A (ru) 2006-03-27
WO2004076665A3 (en) 2005-02-24
US20060147458A1 (en) 2006-07-06
JP2007524352A (ja) 2007-08-30
IS7956A (is) 2005-07-25
MXPA05009160A (es) 2005-10-20
NO20054102L (no) 2005-09-27

Similar Documents

Publication Publication Date Title
GB0226722D0 (en) Vaccine
IL173921A0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0225788D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0323840D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0305794D0 (en) Vaccine
GB0330079D0 (en) Vaccine
GB0321614D0 (en) Vaccines
GB0305793D0 (en) Vaccine
GB0304634D0 (en) Vaccines
GB0212036D0 (en) Vaccines
GB0206595D0 (en) Vaccine
GB0330007D0 (en) Vaccines
GB0300914D0 (en) Vaccines
GB0304635D0 (en) Vaccines
GB0304672D0 (en) Vaccines
GB0300397D0 (en) Vaccines
GB0313737D0 (en) Improved vaccines
GB0223355D0 (en) Vaccine
GB0326757D0 (en) Vaccine
GB0327885D0 (en) Vaccine
GB0329827D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)